Written by: Martina Fraga, PharmD
This purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.
Continue reading Ovarian Cancer: PARP Inhibitor Eligibility
Written by: Michelle Phillips, PharmD, University of Rochester Medical Center
The purpose of this PQI is to highlight key criteria for appropriate monitoring, dosing, and administration to improve the dispensing and management of patients taking niraparib (Zejula).
Continue reading Niraparib: dose modifications based on weight and platelet counts